lebrikizumab
Ebglyss (lebrikizumab) is a monoclonal antibody from Eli Lilly that selectively neutralises interleukin-13, a key driver of type 2 inflammation in atopic dermatitis. It is used in moderate-to-severe disease in adults and adolescents when topical treatment is not enough.
This page is based on FDA prescribing information and the EMA medicine record for lebrikizumab, cross-checked with DailyMed and the National Cancer Institute dictionary; the mechanism is explained in plain language, and analogies are used only where they stay accurate.
How it works
Explains what the medicine does in the body, not dosing, side effects, or safety.
An analogy
Atopic dermatitis is like a faulty alarm circuit that keeps the skin itchy and inflamed, and IL-13 is one of the main wires carrying the alarm. Lebrikizumab clips that specific wire. Other wires, including IL-4's, stay intact, but the alarm's volume drops enough for the skin barrier to repair and the itch to settle.
In simple terms
In atopic dermatitis the immune system overproduces inflammatory signals, and IL-13 is one of the most important. It promotes itching, weakens the skin barrier and keeps inflammation going. Lebrikizumab binds IL-13 and prevents it from activating its receptor. With that signal blocked, itch and redness decrease and the skin has a chance to heal.
In depth
Lebrikizumab is a humanised IgG4 monoclonal antibody that binds IL-13 with high affinity, selectively preventing formation of the IL-13/IL-4R-alpha/IL-13R-alpha1 signalling complex while sparing IL-13R-alpha2 and IL-4 signalling. This suppresses type 2 inflammatory pathways, including IgE production and epithelial barrier dysfunction. Trials demonstrated sustained skin clearance and itch improvement with dosing that can be extended to every four weeks after induction.
See it in motion
A schematic animation of the mechanism — simplified for clarity, not drawn to scale.
How lebrikizumab's IgG4 antibody selectively neutralises IL-13 in atopic dermatitis
- Lebrikizumab is a humanised IgG4 monoclonal antibody that binds IL-13 with high affinity, selectively preventing formation of the IL-13/IL-4R-alpha/IL-13R-alpha1 signalling complex while sparing IL-13R-alpha2 and IL-4 signalling.
- This suppresses type 2 inflammatory pathways, including IgE production and epithelial barrier dysfunction.
- With that signal blocked, itch and redness decrease and the skin has a chance to heal.
- Trials demonstrated sustained skin clearance and itch improvement with dosing that can be extended to every four weeks after induction.
Target: Interleukin-13 (IL-13)
A type 2 cytokine central to the itch, barrier disruption and inflammation of atopic dermatitis; blocking it calms the allergic inflammatory loop without touching IL-4 signalling.
Approved uses
Approved uses differ by country and change over time. Always follow your local prescribing information.
Approved uses in United States
FDA- Treatment of moderate-to-severe atopic dermatitis in adults and children 12 years and older weighing at least 40 kg whose disease is not adequately controlled with topical prescription therapies, or when those therapies are not advisable
Approved uses in European Union
EMA- Treatment of moderate-to-severe atopic dermatitis in adults and adolescents 12 years and older with a body weight of at least 40 kg who are candidates for systemic therapy
Official sources
The statements on this page trace back to these records.
- Ebglyss (lebrikizumab) — Summary of product characteristics and package leaflet, English version
European Medicines Agency
- DailyMed: Ebglyss (lebrikizumab) label
DailyMed, U.S. National Library of Medicine
- U.S. Food and Drug Administration: lebrikizumab prescribing information
U.S. Food and Drug Administration
- National Cancer Institute: lebrikizumab
National Cancer Institute
This page explains how the medicine works — it isn’t the patient leaflet. For anything that applies to you, read the leaflet that came with your medicine or ask your pharmacist.
MedUnfold provides educational content and is not medical advice. Always follow your local prescribing information and healthcare professional.